RootPath Genomics
RootPath Genomics develops a personalized T cell therapy platform utilizing molecular programming-based DNA fragment assembly technology to provide researchers with scalable access to long synthetic genes and their functional readouts. This approach addresses the need for efficient gene function interrogation in precision medicine, enabling faster and more accurate therapeutic development.
- Biotechnology
Updated 11 months ago
Funding
Raised to date
$68MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
across 3 rounds
CINVSCVV+1$50M · Series B
Announced Sep 2021
Disclosed cumulative: $68M
3/3
RoundDateAmountValuationInvestors
Founders
Founder details are not available yet.
Product
Features
- RootPath Genomics develops a personalized T cell therapy platform utilizing molecular programming-based DNA fragment assembly technology to provide researchers with scalable access to long synthetic genes and their functional readouts. This approach addresses the need for efficient gene function interrogation in precision medicine, enabling faster and more accurate therapeutic development.